Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xiaflex: Phase III resumed

AUXL resumed the double-blind, placebo-controlled, U.S. Phase III CORD I trial in 216 patients that was suspended last December

Read the full 192 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE